Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shiran Hoogi"'
Autor:
Shiran Hoogi, Tilda Barliya, Raphaëlle Toledano Zur, Orna Atar, Ifat Abramovich, Eyal Gottlieb, Noga Ron-Harel, Cyrille J Cohen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background T cells play a central role in the antitumor response. However, they often face numerous hurdles in the tumor microenvironment, including the scarcity of available essential metabolites such as glucose and amino acids. Moreover, cancer cel
Externí odkaz:
https://doaj.org/article/16ec3a00ba5d425897d819d2c3231f34
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the function of latter. TIGIT
Externí odkaz:
https://doaj.org/article/c00d8c0f9e2c4f82ac143f6dbdeaf8b4
Autor:
Vasyl Eisenberg, Katerina Shamalov, Shimrit Meir, Shiran Hoogi, Rhitajit Sarkar, Shirel Pinker, Gal Markel, Angel Porgador, Cyrille J. Cohen
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Recent developments in cancer treatment are demonstrating the increasing and powerful potential of immunotherapeutic strategies. In this regard, the adoptive transfer of tumor-specific T-lymphocytes approaches can lead to tumor regression in cancer p
Externí odkaz:
https://doaj.org/article/7cca5c9aebaf41c5811fa65894aefc1e
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Background Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the function of latter. TIGIT (T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4a297c3b3467eef7f7c47e88f240a4d
http://europepmc.org/articles/PMC6734436
http://europepmc.org/articles/PMC6734436
Publikováno v:
Advanced drug delivery reviews. 141
The last decade will be remembered as the dawn of the immunotherapy era during which we have witnessed the approval by regulatory agencies of genetically engineered CAR T-cells and of checkpoint inhibitors for cancer treatment. Understandably, T-lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97caf51e9fcfb98b77f165a5e5f2ffe9
https://pubmed.ncbi.nlm.nih.gov/30653988
https://pubmed.ncbi.nlm.nih.gov/30653988
Autor:
Shiran Hoogi, Cyrille J. Cohen, Vasyl Eisenberg, Shirel Pinker, Angel Porgador, Rhitajit Sarkar, Gal Markel, Shimrit Meir, Katerina Shamalov
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Frontiers in Immunology
Frontiers in Immunology
Recent developments in cancer treatment are demonstrating the increasing and powerful potential of immunotherapeutic strategies. In this regard, the adoptive transfer of tumor-specific T-lymphocytes approaches can lead to tumor regression in cancer p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d989fc2fae0d53846403892ae445c5c6